source
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialMerck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…
- Biotech closures drop to ten in 2026, marking improvement after years of high layoffsFierce's annual "biotech graveyard" list shows ten company closures reported so far in 2026, a sharp decline from sixteen last year and twenty‑seven in 2023. The drop reflects broader easing of bi…